The Cancer Genomics Shared Resource (CGSR) combines state-of-the-art genomic instrumentation with outstanding technical expertise. Members of the Winship Cancer Institute (Winship) benefit from services that facilitate basic science as well as translational research in a CLIA-certified environment. These services are delivered by experienced genomics professionals who ensure that all Instrumentation and procedures are rigorously quality controlled. Recent key equipment purchases underscore the CGSR's focus on new technologies and next generation sequencing for cancer research applications and include an llumina HiScan, Fluidigm Access Array, and lon Torrent Personal Genome Machine. The CSGR has been able to remain price-competitive for services through funding from the Cancer Center Support Grant (5% of annual operating costs) and Winship institutional support (30% of annual operating costs). In the past year, gene expression and methylation array data generated by the CGSR have contributed to high impact publications and successful multi-investigator grant awards including as NASA Specialized Center of Research (PI: Ya Wang, Ph.D.). With new leadership and well defined strategic initiatives, the CGSR is advancing its role in cancer diagnosis and disease classification, risk stratification, and therapeutic decision-making at the Winship Cancer Institute.
The Winship Cancer Genomics Shared Resource allows cancer scientists to conduct sophisticated genome studies that would not otherwise be feasible in their own laboratories. The data generated by the use of this facility lead to a better understanding of the genetic basis of cancer in novel service to cancer treatment and prevention.
|Berg, Carla J; Stratton, Erin; Esiashvili, Natia et al. (2016) Young Adult Cancer Survivors' Experience with Cancer Treatment and Follow-Up Care and Perceptions of Barriers to Engaging in Recommended Care. J Cancer Educ 31:430-42|
|Patel, Kirtesh R; Chowdhary, Mudit; Switchenko, Jeffrey M et al. (2016) BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis. Melanoma Res 26:387-94|
|Horton, John R; Liu, Xu; Gale, Molly et al. (2016) Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds. Cell Chem Biol 23:769-81|
|Yoshida, Michihiro; He, Peijian; Yun, C Chris (2016) Transgenic Expression of Human Lysophosphatidic Acid Receptor LPA2 in Mouse Intestinal Epithelial Cells Induces Intestinal Dysplasia. PLoS One 11:e0154527|
|Bajpai, R; Matulis, S M; Wei, C et al. (2016) Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax. Oncogene 35:3955-64|
|Bonner, Michael Y; Karlsson, Isabella; Rodolfo, Monica et al. (2016) Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo. Oncotarget 7:12857-68|
|Owonikoko, Taofeek K; Zhang, Guojing; Kim, Hyun S et al. (2016) Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer. J Transl Med 14:111|
|Xiao, Canhua; Miller, Andrew H; Felger, Jennifer et al. (2016) A prospective study of quality of life in breast cancer patients undergoing radiation therapy. Adv Radiat Oncol 1:10-16|
|Liu, Min; Wang, Hongyan; Lee, Solah et al. (2016) DNA repair pathway choice at various conditions immediately post irradiation. Int J Radiat Biol 92:819-822|
|Oliver, Daniel E; Patel, Kirtesh R; Switchenko, Jeffrey et al. (2016) Roles of adjuvant and salvage radiotherapy for desmoplastic melanoma. Melanoma Res 26:35-41|
Showing the most recent 10 out of 210 publications